Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists
The DOI matches its Crossref record; 76 of the 79 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 receptor agonists (GLP1RAs) have rapidly changed the landscape of diabetes and obesity treatment. Enthusiasm for their use is tempered with concerns regarding their risk for inducing C-cell tumors based on preclinical studies in rodents. A black-box warning from the US Food and Drug Administration recommends against using GLP1RA in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2A or 2B (MEN2), providing clear guidance regarding this cohort of patients. However, emerging data also suggest an increased incidence of differentiated thyroid cancer (DTC) in patients treated with these agents. Other studies, though, have not confirmed an association between GLP1RAs and DTC. With conflicting results concerning thyroid cancer risk, there is no clear consensus regarding the optimal approach to screening patients prior to initiating the medications and/or evaluating for thyroid cancer during GLP1RA treatment. Within the context of patient cases, this review will summarize the existing data, describe ongoing controversies, and outline future areas for research regarding thyroid cancer risk with GLP1RA use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, all GLP-1s have FDA black box warnings for a potential association with thyroid cancer and long-term data on the safety of the higher doses used for obesity treatment are not yet available [19].”
From Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US (2025) · cites this paper as [19]
Citations
Cites
Management of a Solitary Thyroid Nodule
Desforges, J. F., & Mazzaferri, E. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280807 · Cited by 1,412
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Lin, J. S., Bowles, E. J. A., Williams, S. B., & Morrison, C. C. (2017) · JAMA · doi:10.1001/jama.2017.0562 · Cited by 1,082
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Cited by
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
Bansal, M. B., Patton, H. M., Morgan, T. R. M., Carr, R. M., Dranoff, J. A., & Allen, A. M. (2025) · Hepatology · doi:10.1097/hep.0000000000001608 · Cited by 163
Pearson, S. D., Whaley, C. M., & Emond, S. K. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0083 · Cited by 55
“In addition, all GLP-1s have FDA black box warnings for a potential association with thyroid cancer and long-term data on the safety of the higher doses used for obesity treatment are not yet available [19] .”
Valencia-Rincón, E., Rai, R., Chandra, V., & Wellberg, E. A. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194743 · Cited by 43
“Nonetheless, the FDA issued a warning for most GLP-1R–targeted therapies for patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome, which remains in place today (41).”
Wang, L., Zhang, L., Ma, R., Zhang, Y., Chang, Q., & Yin, D. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf053 · Cited by 29
Metadata
- Authors
- Kelly, C. A., & Sipos, J. A.
- Affiliations
- University Hospitals of Cleveland (US)
- The Ohio State University Wexner Medical Center (US)
- ORCID
- Sipos, Jennifer A
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2024-10-14
- Volume
- 110
- Issue
- 6
- Pages
- e2080-e2087
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W4403398649
- Cited by
- 30
- References
- 79
- Citations by year
- 2026: 20 · 2025: 10
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Keywords
- GLP-1 receptor agonists, thyroid nodules, medullary thyroid carcinoma, multiple endocrine neoplasia type 2, differentiated thyroid cancer, thyroid cancer risk, black box warning, thyroid cancer screening, obesity treatment, diabetes treatment
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Thyroid Neoplasms, Thyroid Nodule, Carcinoma, Neuroendocrine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists. https://app.cochat.ai/papers/10.1210/clinem/dgae722
- The paper
- Kelly, C. A., & Sipos, J. A. (2025). Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae722
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.